In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Feature|Articles|May 21, 2026
Frontline Combos Take the Spotlight: Previewing the Top Hematologic Oncology Presentations at ASCO 2026
Author(s)Chris Ryan, Riley Kandel
Hematologic oncology experts preview the top ASCO 2026 abstracts to watch in myeloma, MPNs, large B-cell lymphoma, and more.
Advertisement
Advertisement
With the
Related to this article
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
Advertisement
Advertisement